ArticleFrontiers in oncology2026
Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: PARP(Poly(ADP-ribose) polymerase) inhibitors are established as effective treatment for ovarian cancer; however, there have been no systematic studies of PARP inhibitor use in older patients with ovarian cancer. Methods: This study was conducted at Peking University People's Hospital. Archival data from patients with advanced age (≥ 65 years) with ovarian cancer between March 2018 and September 2023, who received olaparib or niraparib as maintenance therapy following either first-line platinum-based chemotherapy or platinum-sensitive recurrence (PSR) chemotherapy and achieved complete (CR) or partial response (PR). The two clinical scenarios (first-line maintenance and PSR maintenance) were analyzed separately. Results: Of 56 included patients, 20 (35.7%) and 34 (60.7%) received olaparib and niraparib, respectively, while 2 (3.6%) switched from olaparib to niraparib due to intolerance. The mean age was 70.14 ± 4.63 years. Median progression-free survival (mPFS) was 24 months in 35 (62.5%) patients receiving PARP inhibitors as first-line maintenance therapy(1L-group). In the 1L group, CA125 level, whether CR was reached, Conclusions: PARP inhibitor (olaparib and niraparib) maintenance therapy yields favorable clinical outcomes for elderly ovarian cancer patients. Three clinical factors, attainment R0(no residual disease) after initial surgery, BRCA mutation, and CA-125 ≤10 U/mL before PARP inhibitor treatment, were predictive of longer PFS in elderly ovarian cancer patients undergoing first-line maintenance therapy with PARP inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.